Clinical trials: Refractory Neoplasm
Advanced Cancers, Melanoma
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
The goal of this clinical research study is to find the highest tolerable dose of MGN1703 that can be given in combination with ipilimumab to patients with advanced tumors.
- Trial name
- NCT02668770
- Testing
- MGN1703, Ipilimumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma
Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial is studying how well apolizumab works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma
- Trial name
- NCT00089154
- Testing
- apolizumab, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
The purpose of this study is to determine safety, tolerability, dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory lymphoproliferative malignancies (LPM) or…
- Trial name
- NCT02238522
- Testing
- ZEN003365
- Where
- 4 sites in United States
- Sponsor
- Zenith Epigenetics
Medulloblastoma, Central Nervous System Embryonal Tumor
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells targeting the oncofetal protein Glypican-2 (GPC2) in pediatric and young…
- Conditions
- Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma
- Trial name
- NCT07087002
- Testing
- GPC2-CAR T cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
B Cell Lymphoma, Multiple Mieloma
Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints.
- Trial name
- CARBIOM (NCT07852377)
- Testing
- Biological sample collection and immunomonitoring
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Henri Becquerel
Prostate Cancer
Study of CEP-701 in Treatment of Prostate Cancer
The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.
- Trial name
- NCT00081601
- Testing
- CEP-701
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cephalon
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT07082686
- Testing
- ICP-248
- Where
- 29 sites in China
- Volunteers
- 75 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed Refractory Multiple Myeloma (RRMM)
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of…
- Trial name
- NCT07831122
- Testing
- Belamaf, Cevostamab, Pomalidomide
- Where
- 7 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Canadian Myeloma Research Group
Hepatocellular Carcinoma
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Patients with advanced HCC, refractory to atezolizumab and bevacizumab /IO-based therapy will be treated with pembrolizumab and lenvatinib.
- Trial name
- NCT05101629
- Testing
- Pembrolizumab, Lenvatinib Capsules
- Where
- 12 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
DLBCL - Diffuse Large B Cell Lymphoma
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient…
- Trial name
- NCT06299553
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Incyte Biosciences Italy S.r.l
B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).
- Trial name
- NCT03671460
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tianjin Mycure Medical Technology Co., Ltd
Unspecified Adult Solid Tumor, Protocol Specific
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the…
- Trial name
- NCT00004059
- Testing
- 7-hydroxystaurosporine, fluorouracil
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neuroblastoma
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy…
- Trial name
- NCT03107988
- Testing
- Lorlatinib, Cyclophosphamide, Topotecan
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Hormone-Resistant Prostate Cancer, Recurrent Prostate Carcinoma
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
This randomized phase II trial is studying how well giving pazopanib with or without bicalutamide works in treating patients with prostate cancer that did not respond to hormone therapy.
- Trial name
- NCT00486642
- Testing
- Bicalutamide, Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 6 sites in Canada
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
This is a two strata Phase 1b study to assess the safety and efficacy of bisantrene (RC110) in combination with a) cytarabine arabinoside (Ara-C) treatment for patients with relapsed or refractory (R/R) Acute Myeloid Leukemia…
- Conditions
- Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Higher Risk Myelodysplastic Syndrome
- Trial name
- BISECT (NCT05456269)
- Testing
- Bisantrene Dihydrochloride (high dose), Bisantrene Dihydrochloride (low dose), Cytarabine Hydrochloride
- Where
- Australia
- Sponsor
- Racura Oncology Ltd
Prostate Cancer, Neoplasm Metastasis
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223 in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00459654
- Testing
- Radium-223 dichloride (BAY88-8223), Saline
- Where
- 3 sites in Sweden, United Kingdom
- Volunteers
- 64 people
- Sponsor
- Bayer
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
This phase II MATCH treatment trial identifies the effects of crizotinib in patients whose cancer has a genetic change called ALK rearrangement.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439266
- Testing
- Crizotinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Solid Tumors, Lymphomas
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
This is a double-blind (vis-a-vis lenvatinib), randomized, placebo-controlled, three-treatment, three-way crossover study in healthy subjects. There are two phases in this study: Pre-Randomization and Randomization.
- Trial name
- NCT01525394
- Testing
- Lenvatinib, Moxifloxacin 400 mg
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Tumors
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
The purpose of this study is to determine the safety of bavituximab when administered via a vein, and to examine how bavituximab behaves in the body - how quickly it is taken up by the body and how long it stays there.
- Trial name
- NCT00129337
- Testing
- Bavituximab
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Peregrine Pharmaceuticals
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT06723457
- Testing
- Biospecimen Collection, Computed Tomography, Epcoritamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Reem Karmali
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.